Company profile
PALISADE BIO, INC.
NASDAQ:PALIBiotechnology: Biological Products (No Diagnostic Substances)
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07428096 | phase1 | active_not_recruiting | 2025-10-17 | 2026-01-30 | Palisade Bio | A Study of PALI-2108 in Healthy Volunteers, Patients With Ulcerative Colitis, and Patients With Fibrostenosing Crohn's Disease |
| NCT05470387 | phase3 | terminated | 2022-06-28 | 2023-03-06 | Palisade Bio | A Study to Evaluate LB1148 for Return of Bowel Function in Subjects Undergoing Bowel Resection |
| NCT02836470 | phase2 | completed | 2019-10-01 | 2023-09-06 | Palisade Bio | A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel Resection |
| NCT07845487 | phase2 | recruiting | 2026-08-28 | 2027-10-01 | Palisade Bio | A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis |
| NCT06663605 | phase1 | completed | 2024-11-05 | 2025-07-07 | Palisade Bio | Phase 1 Study Evaluating PALI-2108 in Healthy Volunteers and Ulcerative Colitis Patients. |
FDA applications (0)
No records yet.